Bianchi m 1 becker a hansen j trinh qd tian z abdollah f briganti a shariat sf perrotte p montorsi f karakiewicz pi sun m.
Renal cell carcinoma survival after nephrectomy.
Renal cell carcinoma is the sixth most common cancer in the usa 1 where incidence rates have continued to rise in recent years 2 the prognosis of patients after a rcc diagnosis may follow an heterogeneous course on which the 5 year cancer specific survival rates may be as low as 38 in those patients with locally advanced or node positive disease 3 4.
No significant differences in response rate or progression free survival were observed.
Changes in future survival probability over time.
The median overall survival was 18 4 months in the sunitinib alone group and 13 9 months in the nephrectomy sunitinib group.
Abstract background cytoreductive nephrectomy has been the standard of care in metastatic renal cell carcinoma for 20 years supported by randomized trials and large retrospective studies.
1 for patients with locally advanced tumors 5 year cancer specific survival rates after nephrectomy decrease to 20 to 53 1 and once rcc has metastasized the 5 year survival rate is less than 10.
Adverse events were as anticipated in each group.
Survival rates for renal cell carcinoma are sometimes based on the percentage.